Pancreatic Ductal Adenocarcinoma (PDAC) is the fourth most common cause of cancer-
related death and is the most lethal of common malignancies with a five-year survival rate …

Background Previous studies have revealed the role of dysregulated urokinase
plasminogen activator (encoded by PLAU) expression and activity in several pathways …

Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis among solid
malignancies and improved therapeutic strategies are needed to improve outcomes. Patient …

Pancreatic ductal adenocarcinoma (PDAC) is the most challenging type of cancer to treat,
with a 5-year survival rate of< 10%. Furthermore, because of the large portion of the …

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal human malignant tumor, with a
dismal 5-year survival rate of less than 5%. The lack of specific symptoms at early tumor …

Patient-derived xenograft (PDX) and their xenograft-derived organoid (XDO) models that
recapitulate the genotypic and phenotypic landscape of patient cancers could help to …

Background Pancreatic cancer remains a fatal disease. Experimental systems are needed
for personalized treatment strategies, drug testing and to further understand tumor biology …

Despite advances in diagnostics, less than 5% of patients with periampullary tumors
experience an overall survival of five years or more. Periampullary tumors are neoplasms …

We previously reported that pentagamavunone-1 (PGV-1) effectively inhibited cell
proliferation in many types of human tumors, including pancreatic cancer, by inducing M …

Sarcomas are rare cancers with limited treatment options. Patients are generally treated by
chemotherapy and/or radiotherapy in combination with surgery, and would benefit from new …